RT Journal Article
SR Electronic
T1 Awareness about the risk of hearing loss after ototoxic treatments in Swiss childhood cancer survivors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.23.24314181
DO 10.1101/2024.09.23.24314181
A1 Jörger, Philippa
A1 Nigg, Carina
A1 Žarković, Maša
A1 Sommer, Grit
A1 Kompis, Martin
A1 Michel, Gisela
A1 Ansari, Marc
A1 Waespe, Nicolas
A1 Kuehni, Claudia E.
YR 2024
UL http://medrxiv.org/content/early/2024/09/25/2024.09.23.24314181.abstract
AB Objectives The International Guideline Harmonization Group recommends childhood cancer survivors (CCS) exposed to ototoxic treatments be aware of the risk of hearing loss. We assessed awareness among adult CCS.Methods We identified adults diagnosed with cancer <20 years who received ototoxic treatments through the Swiss Childhood Cancer Registry (ChCR) and invited them to the HEAR-study. Participants completed a questionnaire and underwent pure-tone audiometry. Cancer and treatment data came from the ChCR. We used logistic regression to explore factors influencing awareness.Results 105 of 424 invited CCS participated (25%). 57% did not remember receiving information on hearing loss prior to the study. CCS who remembered being informed were more likely diagnosed after 1995 (OR: 4.5, 95% CI: 1.3-15.4), reported hearing problems (10.9, 2.6-45.1) and other late effects (4.1, 1.3-13.2), and treated with platinum chemotherapy only (10.8, 2.2-53.2) versus cranial radiotherapy only. 44% of participants presented clinically relevant hearing loss.Conclusions Over half of CCS exposed to ototoxic treatments were unaware of their risk of hearing loss.Practice Implications Educating CCS about potential late effects of ototoxic treatments is important to allow early diagnosis and treatment, especially for those who had cancer longer ago and those exposed to cranial radiation.HighlightsHalf of CCS exposed to ototoxic treatment were unaware of the risk of hearing lossCCS treated before 1995 were less aware about the risk of hearing lossInformation provision is key to effective monitoring and early interventionCompeting Interest StatementNicolas Waespe reports a relationship with Swedish Orphan Biovitrum AB that includes advisory board membership, consulting, and travel reimbursement and a relationship with Novartis that includes advisory board membership. None of these relationships are in association with the current study.Clinical Protocols https://preprints.jmir.org/preprint/63627 Funding StatementThis work was financially supported by the Swiss Cancer League and Swiss Cancer Research (grant number HSR-4951-11-2019, KLS/KFS-5711-01-2022, and KFS-5302-02-2021). The CANSEARCH foundation, Kinderkrebs Schweiz Foundation, and Zoe4Life Foundation supported NW.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Canton of Bern gave ethical approval for this work. (166/2014; 2021-01624)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsASHAAmerican Speech-Language-Hearing AssociationCCSChildhood cancer survivorCOGChildren’s Oncology GroupCIConfidence intervalIQRInterquartile rangeGyGray